| pubmed-article:8201379 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8201379 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:8201379 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:8201379 | lifeskim:mentions | umls-concept:C0392920 | lld:lifeskim |
| pubmed-article:8201379 | lifeskim:mentions | umls-concept:C0016441 | lld:lifeskim |
| pubmed-article:8201379 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:8201379 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:8201379 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8201379 | pubmed:dateCreated | 1994-7-1 | lld:pubmed |
| pubmed-article:8201379 | pubmed:abstractText | This study attempted to determine the efficacy of the combination of etoposide (VP-16), methyl-prednisolone, and cytarabine (Ara-C) with or without cisplatin in relapsing and refractory adult lymphoma patients. | lld:pubmed |
| pubmed-article:8201379 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8201379 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8201379 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8201379 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8201379 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8201379 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8201379 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8201379 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8201379 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8201379 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8201379 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:CabanillasFF | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:McLaughlinPP | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:TuckerSS | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:RubensteinEE | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:RodriguezM... | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:HagemeisterF... | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:VelasquezW... | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:SwanFF | lld:pubmed |
| pubmed-article:8201379 | pubmed:author | pubmed-author:RomagueraJJ | lld:pubmed |
| pubmed-article:8201379 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8201379 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:8201379 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8201379 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8201379 | pubmed:pagination | 1169-76 | lld:pubmed |
| pubmed-article:8201379 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:meshHeading | pubmed-meshheading:8201379-... | lld:pubmed |
| pubmed-article:8201379 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8201379 | pubmed:articleTitle | ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. | lld:pubmed |
| pubmed-article:8201379 | pubmed:affiliation | Section of Lymphoma, M.D. Anderson Cancer Center, Houston, TX. | lld:pubmed |
| pubmed-article:8201379 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8201379 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8201379 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8201379 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8201379 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8201379 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8201379 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8201379 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8201379 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8201379 | lld:pubmed |
